Renal effects of non-tenofovir antiretroviral therapy in patients living with HIV
| Autor: | Andrew Merker, Aimee J Guerrero, Milena M. McLaughlin |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty kidney Efavirenz 030106 microbiology antiretroviral therapy Review urologic and male genital diseases Gastroenterology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Indinavir Internal medicine medicine 030212 general & internal medicine highly active Pharmacology Kidney business.industry Cobicistat Stavudine urolithiasis lcsh:RM1-950 General Medicine Raltegravir kidney diseases Atazanavir medicine.anatomical_structure lcsh:Therapeutics. Pharmacology chemistry anti-HIV agents Dolutegravir Molecular Medicine business medicine.drug HIV infections nephrolithiasis |
| Zdroj: | Drugs in Context, Vol 7, Pp 1-15 (2018) Drugs in Context |
| ISSN: | 1740-4398 |
| Popis: | A review of literature published regarding non-tenofovir antiretroviral agents causing renal adverse effects was conducted. The literature involving renal adverse effects and antiretroviral therapy is most robust with protease inhibitors, specifically atazanavir and indinavir, and includes reports of crystalluria, leukocyturia, nephritis, nephrolithiasis, nephropathy and urolithiasis. Several case reports describe potential nephropathy (including Fanconi syndrome) secondary to administration of abacavir, didanosine, lamivudine and stavudine. Case reports documented renal events such as acute renal failure, nephritis, proteinuria and renal stones with efavirenz administration. Regarding rilpivirine, a small increase of serum creatinine levels (SCr) was found in clinical trials; however, the clinical significance and impact on actual renal function is unknown. The integrase strand transfer inhibitors and enfuvirtide have a relatively safe renal profile, although studies have shown dolutegravir and raltegravir cause mild elevations in SCr without an impact on actual renal function. This is similar to the reaction observed with cobicistat, the pharmacokinetic enhancer frequently given with elvitegravir. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|